OPT.AX - Opthea Limited

ASX - ASX Delayed Price. Currency in AUD
3.7400
+0.2100 (+5.95%)
As of 4:11PM AEDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.5300
Open3.6000
Bid3.7600 x 0
Ask3.7900 x 0
Day's Range3.6000 - 3.8600
52 Week Range0.5300 - 4.1500
Volume574,252
Avg. Volume1,197,825
Market Cap919.782M
Beta (3Y Monthly)-4.07
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateAug 16, 2016 - Aug 20, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2004-10-11
1y Target Est1.29
  • GlobeNewswire

    Opthea Presents Additional Data from OPT-302 Phase 2b Wet AMD Trial at the Ophthalmology Innovation Summit in San Francisco

    MELBOURNE, Australia, Oct. 14, 2019 -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye.

  • We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely
    Simply Wall St.

    We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Opthea to Present at the Ophthalmology Innovation Summit in San Francisco

    Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at the Ophthalmology Innovation Summit (OIS) in San Francisco on Thursday, 10th October, 2019 (US Pacific Daylight Time). Dr Baldwin’s presentation will be made in the “Public Company Spotlight” session of the OIS (https://ois.net/ois-aao-2019/agenda/). The presentation of the Company’s Phase 2b randomised, controlled study of OPT-302 with Lucentis® (ranibizumab) compared to Lucentis alone will include an overview of the study design, safety outcomes and primary and secondary outcomes of the study.

  • Is Opthea Limited's (ASX:OPT) CEO Pay Justified?
    Simply Wall St.

    Is Opthea Limited's (ASX:OPT) CEO Pay Justified?

    Megan Baldwin became the CEO of Opthea Limited (ASX:OPT) in 2014. This report will, first, examine the CEO...

  • GlobeNewswire

    Opthea Presents Positive Data from OPT-302 Phase 2b Wet AMD Trial at EURETINA Congress

    MELBOURNE, Australia, Sept. 06, 2019 -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today.

  • GlobeNewswire

    Opthea’s Phase 2b Study of OPT-302 in Wet AMD to be Presented in Late-Breaking Session of EURETINA

    MELBOURNE, Australia, Sept. 04, 2019 -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today.

  • When Will Opthea Limited (ASX:OPT) Become Profitable?
    Simply Wall St.

    When Will Opthea Limited (ASX:OPT) Become Profitable?

    Opthea Limited's (ASX:OPT): Opthea Limited develops and commercializes therapies primarily for eye disease in...

  • GlobeNewswire

    Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD

    OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® Company to Host Conference Call Today at 9:00 AM AEST7:00PM EDT (Tuesday, August 6th.

  • GlobeNewswire

    Opthea to Host Investor Teleconference

    MELBOURNE, Australia, Aug. 05, 2019 -- Opthea Limited (ASX:OPT) will host a conference call to discuss the results of the Company’s Phase 2b clinical trial of OPT-302 in.

  • GlobeNewswire

    Opthea’s Patent Application Covering OPT-302 to be Granted by European Patent Office

    Opthea Limited (ASX:OPT) is pleased to announce that the European Patent Office (EPO) has issued a “Notice of Intention to Grant” in relation to Opthea’s European patent application covering OPT-302, a soluble form of Vascular Endothelial Growth Factor Receptor (VEGFR-3) that binds and inhibits the activity of VEGF-C and VEGF-D. The European patent will cover both the OPT-302 product and compositions containing OPT-302 for use in treating disorders associated with aberrant angiogenesis and/or lymphangiogenesis, including eye diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).  The patent term will extend to February 13, 2034.  Patents covering OPT-302 and extending out to 2034 have now been granted in the U.S.A., Japan, Australia, South Africa and Singapore and applications have been accepted for grant by the EPO, in Malaysia and in Russia.  Patent applications remain pending in 11 other jurisdictions.

  • How Much Are Opthea Limited (ASX:OPT) Insiders Taking Off The Table?
    Simply Wall St.

    How Much Are Opthea Limited (ASX:OPT) Insiders Taking Off The Table?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • How Much Of Opthea Limited (ASX:OPT) Do Institutions Own?
    Simply Wall St.

    How Much Of Opthea Limited (ASX:OPT) Do Institutions Own?

    If you want to know who really controls Opthea Limited (ASX:OPT), then you'll have to look at the makeup of its share...

  • GlobeNewswire

    Opthea Completes Final Patient Visit in Phase 2b Wet AMD Clinical Trial

    Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, announced today that the final patient in the Company’s Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) has completed their last clinical visit. “The final patient's last visit is an important milestone in the clinical development pathway for OPT-302, as it paves the way for the company to finalise data cleaning activities, with top-line results expected to be reported within the coming months,” commented Dr Megan Baldwin, CEO & Managing Director, Opthea Limited.

  • A Holistic Look At Opthea Limited (ASX:OPT)
    Simply Wall St.

    A Holistic Look At Opthea Limited (ASX:OPT)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Attractive stocks have exceptional fundamentals. In the case of Opthea Limited (ASX:OPT), th...

  • GlobeNewswire

    Opthea’s Phase 2b Trial in Wet AMD Advances with a Second Positive Independent Safety Committee Recommendation

    The DSMB did not identify any safety concerns in wet AMD patients administered OPT-302 in combination with Lucentis® (ranibizumab) and unanimously recommended that the study continue as planned with a third, and likely final, meeting of the DSMB to be held following the completion of dosing and the week 24 follow-up visit by all patients enrolled in the study.

  • GlobeNewswire

    Opthea Granted Japanese Patent Covering OPT-302

    MELBOURNE, Australia, Jan. 29, 2019 -- Opthea Limited (ASX:OPT) is pleased to announce the grant of Japanese Patent Number 6408492 covering its OPT-302 soluble VEGFR-3.

  • Is Opthea Limited’s (ASX:OPT) CEO Pay Justified?
    Simply Wall St.

    Is Opthea Limited’s (ASX:OPT) CEO Pay Justified?

    Megan Baldwin became the CEO of Opthea Limited (ASX:OPT) in 2014. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snap Read More...

  • How Financially Strong Is Opthea Limited (ASX:OPT)?
    Simply Wall St.

    How Financially Strong Is Opthea Limited (ASX:OPT)?

    Opthea Limited (ASX:OPT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is OPT will Read More...

  • GlobeNewswire

    Opthea Confirms Final Patient Enrolment in Phase 2b Wet AMD Clinical Trial

    Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, is pleased to report that the last patient has been enrolled in the Company’s ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) and the final number of patients is confirmed as 366. Today’s announcement follows the randomization of an additional 15 patients who were undergoing eligibility screening when the Company recently successfully achieved its target enrolment of 351 treatment naïve patients into the study.  With patient enrolment into the Phase 2b trial now closed, Opthea is currently focused on the completion of all patient dosing and data collection.  The Company expects to report top-line primary outcomes results from this study in the fourth quarter of 2019, significantly ahead of the original projected timelines.

  • GlobeNewswire

    Opthea Completes Patient Recruitment Ahead of Schedule in Phase 2b Wet AMD Clinical Trial

    Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, today announced that recruitment into the Company’s ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) is complete. The randomization of 351 treatment naïve patients with wet AMD at 113 clinical sites in the United States, Europe and Israel was initiated in late December 2017 and has been completed ahead of the projected timelines.